Publications by authors named "Anna Baiguini"
Article Synopsis
- Anticancer treatments often face challenges due to resistant tumor cells that enhance their survival and spread, making finding effective solutions crucial.
- The review discusses mebendazole (MBZ), an antiparasitic drug being explored as a potential cancer treatment, particularly against resistant cancer stem cells.
- Mebendazole has a favorable safety profile, is cost-effective, and shows promise in inhibiting tumor growth, reducing metastasis, and improving survival when used alone or alongside chemotherapy, though more research is needed to confirm its clinical efficacy.
Aim: To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC).
Patients And Methods: Fifty patients with EGFR-mutated or ALK rearrangement-positive NSCLC were treated at our Institution. Radiotherapy was delivered before, after or concomitantly with tyrosine kinase inhibitors (TKIs).
Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.
View Article and Find Full Text PDF